Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRO-122 vs Krytantek Ofteno in Glaucoma or Ocular Hypertension
NCT03257813Phase 3Completed
- Sponsor
- Laboratorios Sophia
- Start
- Apr 2016
- Primary completion
- Mar 2017
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of dorzolamide + timolol + brimonidine in primary open-angle glaucoma (POAG) and ocular hypertension (2 arms), sponsored by Laboratorios Sophia. Primary endpoint: Intraocular Pressure at Day 60. Started Apr 2016; status: completed.
02
Drugs
dorzolamide + timolol + brimonidine
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT03257813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03257813.